Welcome to United Therapeutics Global Medical Affairs.

This website is a resource intended for U.S. healthcare professionals only. This site is intended to provide balanced, scientific, and evidence-based information to foster scientific exchange. United Therapeutics does not provide medical advice. It is the healthcare professional’s responsibility to use independent clinical judgment when making clinical decisions for individual patients.

This website may include information that has not been approved by the U.S. Food and Drug Administration. United Therapeutics does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the FDA-approved product labeling.

Are you a U.S. Healthcare Professional?

 Skip to main content

FREEDOM EV Publication Resources and Contact Information

Publications

This content is being provided in response to your request for information. No further reproduction or distribution is permitted.

Some information contained in this content may be outside of the approved Prescribing Information. This information is not intended to endorse or offer recommendations for administration of this product in a manner inconsistent with the Prescribing Information.

For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the FDA-approved product labeling.

FREEDOM-EV risk analysis manuscript

Contemporary Risk Scores Predict Clinical Worsening in Pulmonary Arterial Hypertension - An Analysis of FREEDOM-EV

Benza RL et al. JHLT 2022.

Read the publication

FREEDOM-EV & OLE long-term survival data

Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open- Label Extension

Grünig et al. Adv Ther

Read the publication

FREEDOM-EV win ratio analysis abstract and poster

Win Ratio Analysis of the FREEDOM-EV Trial - a Hierarchical Approach to Multiple Clinical Endpoints

White RJ et al. Poster presented at: ATS 2023.

Read the Abstract Open the Poster

FREEDOM-EV OLE triple therapy abstract

Oral treprostinil as part of a triple therapy PAH regimen: analysis from FREEDOM-EV Open-Label Extension

Elwing et al. Poster presented at: CHEST 2022.

Read the Abstract

FREEDOM-EV clinical improvement abstract and poster

Clinical Improvement in Patients Treated with Oral Treprostinil: A Post Hoc Analysis of the FREEDOM-EV Study

Sahay S et al. Poster presented at: ATS 2021.

Read the Abstract Open the Poster

FREEDOM-EV dose response abstract and poster

Dose-Response Relationship of Oral Treprostinil for Secondary Endpoints in the FREEDOM-EV Study

White RJ et al. Poster presented at: ERS 2019.

Read the Abstract Open the Poster

Have a question?

Medical Affairs professionals are available to help with questions regarding UT products.

Call us at: 1-877-522-2950

Email us at: medicalinformation@unither.com